Ana Martínez focuses on GSK-3, Biochemistry, Pharmacology, Enzyme and Enzyme inhibitor. Her GSK-3 study combines topics in areas such as Glycogen synthase, Disease, Protein kinase A and Diabetes type ii. Her Biochemistry study integrates concerns from other disciplines, such as Alzheimer's disease and Tau-protein kinase.
Her Pharmacology research is multidisciplinary, relying on both Lead compound, Phosphodiesterase, Parkinson's disease and Amyloid. Ana Martínez interconnects IC50 and In vitro in the investigation of issues within Enzyme. Her Enzyme inhibitor study incorporates themes from Acetylcholinesterase, Chemical synthesis and Stereochemistry.
Her primary scientific interests are in Stereochemistry, GSK-3, Molecule, Pharmacology and Biochemistry. Ana Martínez combines subjects such as Endocrinology, Glycogen synthase and Internal medicine with her study of GSK-3. Her Molecule study combines topics in areas such as Crystallography, Photochemistry, Computational chemistry and Metal.
Her research integrates issues of Phosphodiesterase and Disease in her study of Pharmacology. Her Disease research is multidisciplinary, incorporating elements of Neuroscience and Bioinformatics. Her Biochemistry study focuses mostly on Enzyme and Structure–activity relationship.
The scientist’s investigation covers issues in Kinase, Neuroscience, Amyotrophic lateral sclerosis, Molecule and Drug discovery. Her Kinase research focuses on GSK-3 in particular. Her study ties her expertise on Glycogen synthase together with the subject of GSK-3.
Her Neuroscience research integrates issues from Autophagy, Mitophagy and Neurodegeneration. Her work deals with themes such as Chemical physics, Crystallography, Adsorption and Density functional theory, which intersect with Molecule. Her Structure–activity relationship study is associated with Biochemistry.
Her scientific interests lie mostly in GSK-3, Neuroscience, Adsorption, Molecule and Amyotrophic lateral sclerosis. To a larger extent, Ana Martínez studies Biochemistry with the aim of understanding GSK-3. Her Biochemistry study combines topics from a wide range of disciplines, such as Melissa officinalis and Lamiaceae.
Her biological study spans a wide range of topics, including Chemical physics, Electron donor, Self assembled and Density functional theory. Her study in Amyotrophic lateral sclerosis is interdisciplinary in nature, drawing from both Nuclear protein, Pathological, Phosphorylation and Lymphoblast. As a member of one scientific family, Ana Martínez mostly works in the field of Structure–activity relationship, focusing on Kinase inhibition and, on occasion, Stereochemistry and IC50.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif.
Autophagy (2021)
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
Ana Martinez;Mercedes Alonso;Ana Castro;Concepción Pérez.
Journal of Medicinal Chemistry (2002)
Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
Ana Martinez;Ana Castro;Isabel Dorronsoro;Mercedes Alonso.
Medicinal Research Reviews (2002)
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.
Hagit Eldar-Finkelman;Ana Martinez.
Frontiers in Molecular Neuroscience (2011)
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Pilar Munoz-Ruiz;Laura Rubio;Esther Garcia-Palomero;Isabel Dorronsoro.
Journal of Medicinal Chemistry (2005)
Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ Activation
Rosario Luna-Medina;Marta Cortes-Canteli;Mercedes Alonso;Angel Santos.
Journal of Biological Chemistry (2005)
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.
Ana Castro;Ana Martinez.
Current Pharmaceutical Design (2006)
Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE
D. Alonso;I. Dorronsoro;L. Rubio;P. Muñoz.
Bioorganic & Medicinal Chemistry (2005)
Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Ana Castro;Ana Martinez.
Mini-reviews in Medicinal Chemistry (2001)
Donator acceptor map for carotenoids, melatonin and vitamins.
Ana Martínez;Miguel A. Rodríguez-Gironés;Andrés Barbosa;Miguel Costas.
Journal of Physical Chemistry A (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Spanish National Research Council
University of Zaragoza
Universidad Autónoma Metropolitana
University of Twente
Swinburne University of Technology
Harvard University
Microsoft (United States)
Concordia University
Peking University
Tsinghua University
University of Lille
University of Arizona
University of Murcia
Chinese Academy of Sciences
Linköping University
QIMR Berghofer Medical Research Institute
Xi’an Jiaotong-Liverpool University
Society for Conservation Biology Asia Section
Kyoto University